Roy Baynes, Merck Research Laboratories CMO (file photo)
With at least one gastric cancer approval on the line, Merck's Keytruda scores nod for early patients in chemo combo
Big drugmakers such as Merck and Bristol Myers Squibb are on the firing line with the FDA over accelerated oncology approvals that don’t ace their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
